Rahmouni Kamal, Correia Marcelo L G, Haynes William G, Mark Allyn L
Specialized Center of Research in Hypertension Genetics, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Hypertension. 2005 Jan;45(1):9-14. doi: 10.1161/01.HYP.0000151325.83008.b4. Epub 2004 Dec 6.
Obesity is strongly associated with hypertension and cardiovascular disease. Several central and peripheral abnormalities that can explain the development or maintenance of high arterial pressure in obesity have been identified. These include activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system. Obesity is also associated with endothelial dysfunction and renal functional abnormalities that may play a role in the development of hypertension. The continuing discovery of mechanisms regulating appetite and metabolism is likely to lead to new therapies for obesity-induced hypertension. Better understanding of leptin signaling in the hypothalamus and the mechanisms of leptin resistance should facilitate therapeutic approaches to reverse the phenomenon of selective leptin resistance. Other hunger and satiety signals such as ghrelin and peptide YY are potentially attractive therapeutic strategies for treatment of obesity and its complications. These recent discoveries should lead to novel strategies for treatment of obesity and hypertension.
肥胖与高血压及心血管疾病密切相关。已确定了几种可解释肥胖中动脉高压发生或维持的中枢和外周异常情况。这些包括交感神经系统和肾素 - 血管紧张素 - 醛固酮系统的激活。肥胖还与内皮功能障碍和肾功能异常有关,这些可能在高血压的发生中起作用。对调节食欲和代谢机制的不断发现可能会带来针对肥胖诱导型高血压的新疗法。更好地理解下丘脑的瘦素信号传导以及瘦素抵抗机制应有助于采取治疗方法来逆转选择性瘦素抵抗现象。其他饥饿和饱腹感信号,如胃饥饿素和肽YY,是治疗肥胖及其并发症潜在有吸引力的治疗策略。这些最新发现应会带来治疗肥胖和高血压的新策略。